These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 33002437)

  • 1. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
    Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
    Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
    Sargos P; Chabaud S; Latorzeff I; Magné N; Benyoucef A; Supiot S; Pasquier D; Abdiche MS; Gilliot O; Graff-Cailleaud P; Silva M; Bergerot P; Baumann P; Belkacemi Y; Azria D; Brihoum M; Soulié M; Richaud P
    Lancet Oncol; 2020 Oct; 21(10):1341-1352. PubMed ID: 33002438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
    Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
    BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
    Parker CC; Clarke NW; Cook AD; Kynaston HG; Petersen PM; Catton C; Cross W; Logue J; Parulekar W; Payne H; Persad R; Pickering H; Saad F; Anderson J; Bahl A; Bottomley D; Brasso K; Chahal R; Cooke PW; Eddy B; Gibbs S; Goh C; Gujral S; Heath C; Henderson A; Jaganathan R; Jakobsen H; James ND; Kanaga Sundaram S; Lees K; Lester J; Lindberg H; Money-Kyrle J; Morris S; O'Sullivan J; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Røder MA; Sayers I; Simms M; Wilson J; Zarkar A; Parmar MKB; Sydes MR
    Lancet; 2020 Oct; 396(10260):1413-1421. PubMed ID: 33002429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
    Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
    Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
    Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
    Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment results of adjuvant radiotherapy and salvage radiotherapy after radical prostatectomy for prostate cancer.
    Wadasaki K; Kaneyasu Y; Kenjo M; Matsuura K; Murakami Y; Hashimoto Y; Ito K; Kiriu H; Ito A
    Int J Clin Oncol; 2007 Feb; 12(1):37-41. PubMed ID: 17380439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
    Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
    Vale CL; Fisher D; Kneebone A; Parker C; Pearse M; Richaud P; Sargos P; Sydes MR; Brawley C; Brihoum M; Brown C; Chabaud S; Cook A; Forcat S; Fraser-Browne C; Latorzeff I; Parmar MKB; Tierney JF;
    Lancet; 2020 Oct; 396(10260):1422-1431. PubMed ID: 33002431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).
    Parker CC; Petersen PM; Cook AD; Clarke NW; Catton C; Cross WR; Kynaston H; Parulekar WR; Persad RA; Saad F; Bower L; Durkan GC; Logue J; Maniatis C; Noor D; Payne H; Anderson J; Bahl AK; Bashir F; Bottomley DM; Brasso K; Capaldi L; Chung C; Cooke PW; Donohue JF; Eddy B; Heath CM; Henderson A; Henry A; Jaganathan R; Jakobsen H; James ND; Joseph J; Lees K; Lester J; Lindberg H; Makar A; Morris SL; Oommen N; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Ramani V; Røder A; Sayers I; Simms M; Srinivasan V; Sundaram S; Tarver KL; Tran A; Wells P; Wilson J; Zarkar AM; Parmar MKB; Sydes MR;
    Ann Oncol; 2024 Jul; 35(7):656-666. PubMed ID: 38583574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.